Cogent Biosciences to Present SUMMIT Trial Data on Bezuclastinib at AAAAI 2026
Event summary
- Cogent Biosciences will present six posters on bezuclastinib results from the SUMMIT trial at the 2026 AAAAI Annual Meeting (Feb 27-Mar 2).
- The posters detail expanded Phase 2 trial data, bone formation marker changes, patient experience, symptom burden improvement, and subgroup analyses.
- Cogent submitted a New Drug Application for bezuclastinib in NonAdvSM to the FDA in December 2025, following Breakthrough Therapy Designation.
The big picture
Cogent Biosciences is advancing its lead candidate, bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation in NonAdvSM. The upcoming AAAAI presentations come as the company seeks FDA approval following its December 2025 NDA submission. Success here could position Cogent as a key player in precision therapies for genetically defined diseases, though it faces competition from established treatments.
What we're watching
- Regulatory Timeline
- Whether the FDA will expedite review of bezuclastinib given its Breakthrough Therapy Designation and the positive SUMMIT trial data.
- Clinical Efficacy
- How the detailed symptom improvement and subgroup data from AAAAI will impact investor confidence in bezuclastinib's commercial potential.
- Competitive Positioning
- The pace at which Cogent can differentiate bezuclastinib from existing treatments for NonAdvSM, particularly avapritinib.
Related topics